PDF(Pubmed)
Abstract：
The aim was clinical evaluation of the efficacy of topical insulin eye drops in patients with refractory persistent epithelial defects (PEDs). This prospective non-randomized investigation was conducted to examine the efficacy of insulin eye drops in treating patients with PEDs that did not respond to conventional therapy. A total of twenty-three patients were included in the study, and they were administered insulin eye drops formulated as 1 U/mL, four times a day. The rate of epithelial defect resolution and time to complete corneal re-epithelialization were considered primary outcome measures. The relative prognostic impact of initial wound size and other parameters, including age, sex, smoking, diabetes, and hypertension were also analyzed. The results showed that during follow-up (maximum 50 days), a total of 16 patients (69.6%) achieved improvement. Insulin eye drops significantly reduced the corneal wounding area in 75% of patients with small epithelial defects (5.5 mm2 or less) during 20 days. Only 61% of patients with moderate epithelial defects (5.51-16 mm2) showed a significant recovery in 20-30 days. Also, 71% of patients with a defect size greater than 16 mm2, demonstrated a significant improvement in the rate of corneal epithelial wound healing in about 50 days. In conclusion topical insulin reduces the PED area and accelerates the ocular surface epithelium wound healing.
摘要：
目的是临床评估局部胰岛素滴眼液对难治性持续性上皮缺损（PEDs）患者的疗效。进行了这项前瞻性非随机研究，以检查胰岛素滴眼液在治疗对常规治疗无反应的PED患者中的疗效。共有23名患者被纳入研究,他们服用胰岛素滴眼液配制为1U/mL，一天四次.上皮缺损消退率和完成角膜上皮再形成的时间被认为是主要结果指标。初始伤口大小和其他参数的相对预后影响，包括年龄,性别,吸烟,糖尿病,和高血压也进行了分析。结果显示，在随访期间（最长50天），共有16例患者(69.6%)获得改善.在20天内，胰岛素滴眼液可显着减少75％的小上皮缺损（5.5mm2或更小）患者的角膜创伤面积。只有61％的中度上皮缺损（5.51-16mm2）患者在20-30天内表现出显着的恢复。此外，71％的缺损大小大于16mm2的患者在约50天内显示出角膜上皮伤口愈合率显着改善。总之，局部胰岛素减少了PED面积，并加速了眼表上皮伤口的愈合。
